Postinflammatory hypopigmentation: a comprehensive review of treatments

Madu, Pamela; Syder, Nicole; Elbuluk, Nada

doi:10.1080/09546634.2020.1793892

Cited by 7 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After removal of the BIA-ALCL and of the capsule, our patient experienced a local mild loss of the pigmentation, which is consistent with a post-inflammatory hypomelanosis, a condition where “individual chromatic tendency” determines the aberration of melanogenesis by multiple immunological mediators [ 14 ] that could have remained in the skin, which was anyway free of neoplastic diseases as biopsy stated.…”

Section: Discussionmentioning

confidence: 56%

A Rare Case of BIA-ALCL Mass Associated with Mastectomy Skin Flap Erythema After Immunization with COVID-19

Garusi

Fiori

et al. 2022

Aesth Plast Surg

View full text Add to dashboard Cite

Background The immune response to breast implants after COVID-19 disease or COVID-19 vaccine administration includes acute inflammatory manifestations, capsular contracture and seroma. Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a very rare tumor in which numerous up-regulated pro-inflammatory immunological pathways activate a T cell lymphoproliferative disorder. Methods The first reported case of a BIA-ALCL hidden mass clinically manifesting with inflammatory signs after SARS-CoV-2 infection and vaccinations is here described. Results Complete capsulectomy and adjuvant chemotherapy were performed and immediately after the surgical procedure local inflammatory signs disappeared; no evidence of disease was present 1 year later. Conclusions Immunological stimulation by COVID-19 disease and vaccines may highlight some rare clinical manifestations of BIA-ALCL; persistent inflammatory symptomatology over breast implants should be investigated using second-level imaging. Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

show abstract

Section: Discussionmentioning

confidence: 56%

A Rare Case of BIA-ALCL Mass Associated with Mastectomy Skin Flap Erythema After Immunization with COVID-19

Garusi

Fiori

et al. 2022

Aesth Plast Surg

View full text Add to dashboard Cite

show abstract

“…In a recent literature review, Madu et al 2 . list many treatments for postinflammatory hypopigmentation, including the laser hole technique using nonfractional CO 2 laser, 35 fractional CO 2 laser, 1,36 fractional CO 2 laser with topical latanoprost, 1,36 1,550‐nm fractional laser with or without topical bimatoprost 36 or with topical tretinoin or pimecrolimus, 37 skin grafting, 36,38–40 needling and noncultured autologous skin cell transplantation, 41 needling and UVA, 42 excimer laser, 43–45 dermabrasion, 39 cosmetic camouflage, 46 and cosmetic tattooing 47 .…”

Section: Discussionmentioning

confidence: 99%

“…Hypochromic lesions caused by external injuries represent one of the great therapeutic challenges in dermatology 1,2 . These lesions can be superficial (hypochromic spots) or associated with changes in skin texture and contour (hypochromic scars).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Is it possible to repigment iatrogenic and traumatic hypochromic lesions? A case series using the MMP^® drug delivery technique with 5‐fluorouracil and bleomycin

Arbache

Arbache²,

Hirata

2021

Int J Dermatology

View full text Add to dashboard Cite

Objectives We present the results of 11 patients with hypochromic lesions treated with antifibrotic agents delivered through the MMP® technique. Methods Eleven patients with hypochromic lesions because of external injuries were treated at a single clinic with 5‐fluorouracil (5‐FU) and/or bleomycin using the MMP® drug delivery technique. Treatment sessions were repeated at 30‐day intervals until patient satisfaction. The primary outcome was repigmentation of the lesions, assessed independently by two dermatologists and by the patient. Results The MMP® technique injected 0.048 mg/cm2 of 5‐FU or 0.0028 U/cm2 of bleomycin. The accumulated 5‐FU and bleomycin density per patient ranged from 0.02 to 0.77 mg and 0.0022 to 0.2800 U/ml, respectively. Patients were treated with 1 to 6 MMP® sessions with 5‐FU (3 patients), bleomycin (6 patients), or both drugs (2 patients). After the last session, all patients had a significant improvement (>75%) of the lesions compared to baseline. There were no procedure‐related short‐ or long‐term adverse effects in any of the participants up to their last follow‐up visit. Conclusions The injection of antifibrotic agents using the MMP® technique was effective and safe in the treatment of hypochromic lesions. This can be a new therapeutic option for these lesions.

show abstract

Treatment of pigmentation disorders in association with systemic diseases

Dănescu

Sălăvăstru²,

Ţiplica

et al. 2020

Hautarzt

View full text Add to dashboard Cite

Postinflammatory hypopigmentation: a comprehensive review of treatments

Cited by 7 publications

References 32 publications

A Rare Case of BIA-ALCL Mass Associated with Mastectomy Skin Flap Erythema After Immunization with COVID-19

A Rare Case of BIA-ALCL Mass Associated with Mastectomy Skin Flap Erythema After Immunization with COVID-19

Is it possible to repigment iatrogenic and traumatic hypochromic lesions? A case series using the MMP^® drug delivery technique with 5‐fluorouracil and bleomycin

Treatment of pigmentation disorders in association with systemic diseases

Contact Info

Product

Resources

About

Postinflammatory hypopigmentation: a comprehensive review of treatments

Cited by 7 publications

References 32 publications

A Rare Case of BIA-ALCL Mass Associated with Mastectomy Skin Flap Erythema After Immunization with COVID-19

A Rare Case of BIA-ALCL Mass Associated with Mastectomy Skin Flap Erythema After Immunization with COVID-19

Is it possible to repigment iatrogenic and traumatic hypochromic lesions? A case series using the MMP® drug delivery technique with 5‐fluorouracil and bleomycin

Treatment of pigmentation disorders in association with systemic diseases

Contact Info

Product

Resources

About

Is it possible to repigment iatrogenic and traumatic hypochromic lesions? A case series using the MMP^® drug delivery technique with 5‐fluorouracil and bleomycin